JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Strona główna・Stock List・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Closed

SectorHealthcare

16.21 -2

Buy Sell

Overview

Share price change

24h

Current

Min

15.9

Max

16.54

Key metrics
By Trading Economics
Income	4.8M -36M
Sales	6.1M 116M
Profit margin	-30.977
Employees	1,869
EBITDA	24M -31M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+134.46% upside

Dividends
By Dow Jones
Next Earnings	26 lut 2026

Market Stats
By TradingEconomics
Market Cap	-1.1B 2B
Previous open	18.21
Previous close	16.21

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

28.13 / 31.12 Support & Resistance

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 lut 2026, 23:52 UTC

Acquisitions, Mergers, Takeovers

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 lut 2026, 23:52 UTC

Acquisitions, Mergers, Takeovers

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 lut 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 lut 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 lut 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 lut 2026, 23:23 UTC

Earnings

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 lut 2026, 22:57 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 lut 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 lut 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 lut 2026, 21:51 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 lut 2026, 21:49 UTC

Earnings

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 lut 2026, 21:39 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 lut 2026, 21:36 UTC

Earnings

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 lut 2026, 21:34 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 lut 2026, 21:28 UTC

Acquisitions, Mergers, Takeovers

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 lut 2026, 21:23 UTC

Earnings

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 lut 2026, 21:19 UTC

Earnings

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 lut 2026, 21:17 UTC

Earnings

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 lut 2026, 21:17 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 lut 2026, 21:10 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 lut 2026, 21:08 UTC

Earnings

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 lut 2026, 21:07 UTC

Earnings

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 lut 2026, 21:05 UTC

Earnings

Palantir Technologies 4Q Net $608.7M >PLTR

2 lut 2026, 21:05 UTC

Earnings

Palantir Technologies 4Q Rev $1.41B >PLTR

2 lut 2026, 21:05 UTC

Earnings

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 lut 2026, 21:05 UTC

Earnings

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 lut 2026, 21:05 UTC

Earnings

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 lut 2026, 21:05 UTC

Earnings

Palantir Technologies 4Q EPS 24c >PLTR

2 lut 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

134.46% upside

12 Months Forecast

Average 38.92 USD 134.46%

High 58 USD

Low 25.7 USD

Based on 4 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Zai Lab Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.